Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Cell Carcinoma of the Bladder: early-phase trial registry
2 of 2 indexed Small Cell Carcinoma of the Bladder trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Small Cell Carcinoma of the Bladder: 2 US clinical trials tracked, 2 recruiting.
Small Cell Carcinoma of the Bladder is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition small-cell-carcinoma-of-the-bladder
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Small Cell Carcinoma of the Bladder lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Cell Carcinoma of the Bladder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Cell Carcinoma of the Bladder is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
National Cancer Institute (NCI)
NCT06161532
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Cancer Institute (NCI)
NCT06228066
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Cell Carcinoma of the Bladder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Cell Carcinoma of the Bladder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Cell Carcinoma of the Bladder page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Small Cell Carcinoma of the Bladder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Small Cell Carcinoma of the Bladder trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Cell Carcinoma of the Bladder condition card totals 2 registered trials; most-linked intervention Lurbinectedin; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.